Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16927650 | 0.87 | XDH (0.44) | KDM4ESRCBRAFKDRNPSR1 | |
| SCHEMBL1304888 | 0.84 | NPBWR1 (0.39) | CYP1A2NR3C1NPSR1LMNAMEN1 | |
| SCHEMBL885439 | 0.84 | PTGS1 (0.43) | CYP1A2KDM4ENPSR1LMNAPTGS2 | |
| SCHEMBL219809 | 0.84 | SMN1; SMN2 (0.41) | CYP1A2KDM4EBRAFNPSR1LMNA | |
| SCHEMBL16927664 | 0.80 | PTGS2 (0.47) | CYP1A2NPSR1LMNAKMT2APTGS2 | |
| SCHEMBL16927613 | 0.80 | NPBWR1 (0.39) | KDM4E | |
| SCHEMBL28417582 | 0.80 | POLB (0.41) | CYP17A1CYP1A2LMNAMEN1KMT2A | |
| SCHEMBL15016131 | 0.78 | PTGS1 (0.46) | NPSR1MEN1KMT2APTGS2PTGS1 | |
| SCHEMBL16927635 | 0.78 | PTGS2 (0.47) | CYP1A2PTGS2PTGS1 | |
| SCHEMBL16927593 | 0.77 | CYP17A1 (0.38) | CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362934-A | Isothiazole oxadiazole derivatives, and preparation method and application thereof | 南开大学 | 2020-07-03 | — | — | CN | claimed |
| CN-111362934-A | Isothiazole oxadiazole derivatives, and preparation method and application thereof | 南开大学 | 2020-07-03 | — | — | CN | disclosed |
| EP-2342196-B1 | PYRAZOLE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | CYP17A1 4637/4885CYP1A2 1874/4885NR3C1 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.